With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Loss of ER-mitochondria contacts drives therapy resistance in neuroblastoma||Children's Hospital of Philadelphia / Michael Hogarty, MD||Innovation Grants||2021||Pennsylvania|
|Characterizing Inflammatory Phenotypes Associated with RUNX1 Deficiency||Dana-Farber Cancer Institute / Waihay Wong, MD/PhD||RUNX1 Early Career Investigator Grants||2021||Massachusetts|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|
|Role of PHF6 Mutations in Germline RUNX1 Deficiency Associated Hematopoietic Disorders||The Regents of the University of California San Francisco / Serine Avagyan, MD/PhD||RUNX1 Early Career Investigator Grants||2021||California|
|Targeting the biological underpinnings of pulmonary metastasis in osteosarcoma||Dana-Farber Cancer Institute / Rani George, MD/PhD||Crazy 8 Awards||2022||Massachusetts|
|GENOME ORIGAMI: Refolding Aberrant Chromosome 3D Structure for Treating NUT Carcinoma||Baylor College of Medicine / Kyle Eagen, PhD||R Accelerated Award Grants||2022||Texas|
|Targeting Kinase Inhibitor Induced DNA-Damage Response in Ph-Like ALL||Temple University / Christian Hurtz, PhD||'A' Award Grants||2022||Pennsylvania|
|Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations||The Regents of the University of Michigan / Jolanta Grembecka, PhD||Reach Grants||2022||Michigan|
|Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma||Dana-Farber Cancer Institute / Rani George, MD, PhD||Innovation Grants||2022||Massachusetts|
|Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy||University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD||Innovation Grants||2022||Wisconsin|